Specialty Renal Products Announces Appointment of Tony Robinson as Vice President of Operations
March 25 2020 - 7:30AM
via NEWMEDIAWIRE -- Specialty Renal Products, Inc. (SRP), a
subsidiary of Nephros, Inc. (Nasdaq:NEPH), a medical device company
that develops and sells a hemodiafiltration (HDF) system for the
treatment of patients with end stage renal disease
(ESRD), announced today that it has hired Tony Robinson as
Vice President of Operations.
“We are extremely pleased to have Tony join the
SRP team,” said Daron Evans, President and Chief Executive Officer.
“Tony brings significant expertise managing medical device
development programs, as well as commercial launch planning. We
anticipate that he will drive significant value for SRP’s
shareholders.”
“I have been following the progress of SRP’s
next-generation HDF system, and I couldn’t be more excited to join
the company at this late stage of development,” said Tony Robinson.
“I believe HDF holds enormous promise and look forward to helping
bring this therapy option to U.S. dialysis patients.”
Tony Robinson brings over 16 years of leadership
in medical device development, operational execution, and
regulatory compliance to SRP, most recently as COO of CVR Medical
Corp. Tony earned a BBA in Finance and an MBA in Health Care
Administration, fueling a career which has spanned both the public
and private sectors. Previously providing guidance to both
start-ups and large global entities, he possesses hands-on
experience in all aspects of the medical device life cycle.
About Specialty Renal Products, Inc. and
Nephros, Inc.
Specialty Renal Products, a subsidiary of Nephros,
is focused on the development of medical device products for
patients with renal disease, including a hemodiafiltration system
for the treatment of patients with ESRD.
Nephros is a commercial stage company that
develops and sells high performance water purification products and
pathogen detection systems to the medical and commercial markets.
Nephros ultrafilters and pathogen detection systems are used in
hospitals and medical clinics to assess and reduce the infection
risks from waterborne pathogens (e.g., Legionella, Pseudomonas) in
showers, sinks, and ice machines. Additionally, Nephros
ultrafilters are used by dialysis centers for assisting in the
added removal of endotoxins and other biological contaminants from
the water and bicarbonate concentrate supplied to hemodialysis
machines and patients.
For more information about Nephros, please visit
its website at www.nephros.com.
Forward-Looking Statements
This release contains forward-looking statements
that are subject to various risks and uncertainties. Such
statements include statements regarding SRP’s strategy, plans and
objectives, and other statements that are not historical facts,
including statements which may be accompanied by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Actual results could
differ materially from those described in these forward-looking
statements due to certain factors, including uncertainty in
clinical outcomes, potential delays in the regulatory approval
process, changes in business, economic and competitive conditions,
the availability of capital when needed, dependence on third party
manufacturers and researchers, regulatory reforms, uncertainties in
litigation or investigative proceedings, and the availability of
financing. These and other risks and uncertainties are detailed in
Nephros’s reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2019. Nephros does not undertake any
responsibility to update the forward-looking statements in this
release.
Investor Relations Contacts
Kirin Smith, President
PCG Advisory, Inc.
(646) 863-6519
ksmith@pcgadvisory.com
Andy Astor, COO & CFO
Nephros, Inc.
(201) 345-0824
andy@nephros.com
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Apr 2023 to Apr 2024